Image-guided radiation therapy developer ViewRay has received clearance from the U.S. Food and Drug Administration (FDA) for new soft-tissue visualization capabilities for its MRIdian MRI-guided radiation therapy system.
The system's new capabilities include expanded high-definition visualization and enhanced contrast between different tissues, a diffusion-weighted imaging feature that tracks treatment progress by distinguishing between tumor and normal tissues, and faster and more detailed anatomical planar imaging, the company said.
The system also features ViewRay's SmartVision MRI, which supports high-fidelity beam delivery; its SmartAdapt software, which allows clinicians to generate daily MR setup scans quickly; and its SmartTarget tool, which images the tumor's edges and surrounding organ position in real-time, according to the firm.
